Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Endocrinol Invest ; 23(5): 321-4, 2000 May.
Article in English | MEDLINE | ID: mdl-10882151

ABSTRACT

Interferon (IFN)-beta has become a widespread therapy for multiple sclerosis. As already reported for IFN-alpha, thyroid autoimmunity and dysfunctions have been observed also in course of IFN-beta therapy. Nevertheless, very few cases of Graves' disease, occurred in such condition, have been reported in literature. We here describe the case of a 40-year-old female affected by multiple sclerosis, who received IFN-beta-1b, 8 million IU s.c. every other day for her condition. After 22 months of cytokine administration, she developed a severe Graves' disease with persistently positive TR-Ab which suggested the withdrawal of the treatment. Our patient had performed a complete thyroid evaluation with normal findings, before and during the first 6 months of therapy. This case suggests that patients undergoing long-term IFN-beta therapy should be monitored for thyroid hormones and antibodies throughout the treatment as thyroidal side effect can be a late event.


Subject(s)
Graves Disease/chemically induced , Interferon-beta/adverse effects , Multiple Sclerosis/drug therapy , Adult , Autoantibodies/blood , Female , Graves Disease/diagnosis , Graves Disease/immunology , Humans , Interferon beta-1a , Interferon beta-1b , Interferon-beta/administration & dosage , Interferon-beta/therapeutic use , Thyroid Gland/immunology , Thyroxine/blood , Triiodothyronine/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...